供体淋巴细胞输注的改良：如何改善治疗结果？ - Suppr

Modification of donor lymphocyte infusion: how to improve the outcome?

作者信息

Wang Yu, Xu Lanping, Yan Chenhua, Huang Xiaojun

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China.

Peking-Tsinghua Center for Life Sciences, Beijing, 100871, China.

出版信息

Sci China Life Sci. 2019 Sep;62(9):1253-1256. doi: 10.1007/s11427-019-9597-3. Epub 2019 Jul 30.

DOI:10.1007/s11427-019-9597-3

PMID:31372818

Abstract

摘要

相似文献

Modification of donor lymphocyte infusion: how to improve the outcome?

Sci China Life Sci. 2019 Sep;62(9):1253-1256. doi: 10.1007/s11427-019-9597-3. Epub 2019 Jul 30.

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia.

Blood. 2007 Jun 1;109(11):5063-4. doi: 10.1182/blood-2007-02-072470.

Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.

J Clin Apher. 2001;16(2):82-7. doi: 10.1002/jca.1017.

Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation.

Immunotherapy. 2016;8(1):57-68. doi: 10.2217/imt.15.100. Epub 2015 Dec 7.

Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.

Cancer Control. 2002 Mar-Apr;9(2):123-37. doi: 10.1177/107327480200900205.

Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.

Bone Marrow Transplant. 2003 Sep;32(5):495-504. doi: 10.1038/sj.bmt.1704150.

Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.

J Hematother Stem Cell Res. 2002 Apr;11(2):265-76. doi: 10.1089/152581602753658457.

Adoptive immunotherapy with donor lymphocyte transfusions.

Curr Opin Oncol. 1997 Mar;9(2):139-45. doi: 10.1097/00001622-199703000-00006.

Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.

Exp Hematol. 2000 Nov;28(11):1225-31. doi: 10.1016/s0301-472x(00)00533-6.

Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy.

Cell Rep. 2021 Nov 9;37(6):109992. doi: 10.1016/j.celrep.2021.109992.

引用本文的文献

Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.

Bone Marrow Transplant. 2025 Mar;60(3):277-285. doi: 10.1038/s41409-024-02466-1. Epub 2024 Nov 16.

Modified Prophylactic Donor Lymphocyte Infusion (DLI) in an Adult T Cell Lymphoma/Leukemia (ATLL) Patient-Modality of Relapse Prevention.

Diseases. 2024 Sep 11;12(9):210. doi: 10.3390/diseases12090210.

[Chinese expert consensus of allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia (2022)].

Zhonghua Xue Ye Xue Za Zhi. 2022 Oct 14;43(10):793-801. doi: 10.3760/cma.j.issn.0253-2727.2022.10.001.

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.

Front Oncol. 2022 Jan 27;11:790299. doi: 10.3389/fonc.2021.790299. eCollection 2021.

Adaptive T cell immunotherapy in cancer.

Sci China Life Sci. 2021 Mar;64(3):363-371. doi: 10.1007/s11427-020-1713-9. Epub 2020 Jul 23.

Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study.

J Hematol Oncol. 2020 Mar 30;13(1):27. doi: 10.1186/s13045-020-00860-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Modification of donor lymphocyte infusion: how to improve the outcome?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献